financetom
Business
financetom
/
Business
/
UiPath Stock Plummets After Q1 Results: Here's Why
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
UiPath Stock Plummets After Q1 Results: Here's Why
May 29, 2024 2:02 PM

UiPath, Inc. ( PATH ) reported its first-quarter financial results and announced a chief executive officer transition after the bell Wednesday. Here's a look at the details from the report. 

The Details: UiPath ( PATH ) reported quarterly earnings of 13 cents per share, which beat the analyst consensus estimate of 12 cents by 8.33%.

Quarterly sales came in at $335 million, which beat the analyst consensus estimate of $333.04 million and represents a 15.68% increase over sales of $289.59 million from the same period last year.

The company reported ARR of $1.508 billion, an increase of 21 percent year-over-year, cash flow from operations was $100 million and non-GAAP adjusted free cash flow was $101 million

“We are pleased to report that ARR surpassed $1.5 billion in the first quarter of fiscal 2025, a testament to our market-leading Business Automation Platform and the strategic role automation plays in digital transformation,” said Daniel Dines, UiPath ( PATH ) founder and chief innovation officer.

“We believe the foundation of our business remains strong and we are optimistic about our ability to drive growth and profitability through improved execution, customer centricity, and continued innovation.”

The company also announced Rob Enslin will resign as CEO and as a member of the UiPath ( PATH ) board of directors, effective June 1, 2024. Daniel Dines, founder and former CEO of UiPath ( PATH ), will be reappointed CEO, also effective June 1, 2024.

Outlook: UiPath ( PATH ) sees second-quarter revenue in the range of $300 million to $305 million and fiscal year 2025 revenue in a range of $1.405 billion and $1.41 billion.

Related News: What’s Going On With AMC Entertainment Stock Today?

PATH Price Action: According to Benzinga Pro, UiPath ( PATH ) shares are down 30.33% after-hours at $12.75 at the time of publication Wednesday.

Image: Courtesy of UiPath, Inc. ( PATH )

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Regional lenders Berkshire Hills Bancorp, Brookline strike $1.1 bln merger deal
Regional lenders Berkshire Hills Bancorp, Brookline strike $1.1 bln merger deal
Dec 16, 2024
Dec 16 (Reuters) - Berkshire Hills Bancorp ( BHLB ) and Brookline Bancorp ( BRKL ) have agreed to merge in an all-stock deal valued at about $1.1 billion, the regional lenders said on Monday. Regional lenders that were at the heart of the banking crisis in 2023 have been cutting more deals this year to expand their geographic foothold...
BBVA Research Sees Two 25bps Rate Cuts At Peru's Central Bank by End Q2 2025 After Last's Week Hold
BBVA Research Sees Two 25bps Rate Cuts At Peru's Central Bank by End Q2 2025 After Last's Week Hold
Dec 16, 2024
08:49 AM EST, 12/16/2024 (MT Newswires) -- The Board of Peru's central bank (BCRP) last week kept the reference interest rate at 5.00%, noted BBA Research. BCRP expected both headline and core inflation to remain within the target range over the projection horizon, pointed out BBVA Research. It also states that economic activity was now around its potential level. BBVA...
Dare Bioscience to Submit Plan for Phase 3 Study of Potential Female Sexual Disorder Treatment
Dare Bioscience to Submit Plan for Phase 3 Study of Potential Female Sexual Disorder Treatment
Dec 16, 2024
08:50 AM EST, 12/16/2024 (MT Newswires) -- Dare Bioscience ( DARE ) and its partner Strategic Science & Technologies said Monday they will submit a protocol and statistical analysis plan to the US Food and Drug Administration in Q1 for a phase 3 study of sildenafil cream, 3.6%, an investigational treatment for female sexual arousal disorder. The companies said they...
Carlyle agrees to sell Italy's Forgital to Stonepeak
Carlyle agrees to sell Italy's Forgital to Stonepeak
Dec 16, 2024
MILAN, Dec 16 (Reuters) - Private equity firm Carlyle has agreed to sell Italian firm Forgital, which manufactures forged components mainly for the aerospace sector, to U.S. alternative investment firm Stonepeak, the two companies said on Monday. The deal gives the Italian company an enterprise value of around 2 billion euros ($2.10 billion), a source close to the matter told...
Copyright 2023-2026 - www.financetom.com All Rights Reserved